2647530-73-0

2647530-73-0 structure

Name: Ensitrelvir
Chemical Name: 1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)-
CAS Number: 2647530-73-0
Molecular Formula: C₂₂H₁₇ClF₃N₉O₂
Molecular Weight: 531.88
Catalog: Signaling Pathways Anti-infection SARS-CoV
Create Date: 2022-03-28 12:44:20
Modify Date: 2025-08-25 17:30:10
Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM)[1][2].

Name	1,3,5-Triazine-2,4(1H,3H)-dione, 6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]dihydro-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-, (6E)-

Description	Ensitrelvir (S-217622) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM)[1][2].
Related Catalog	Research Areas >> Infection Signaling Pathways >> Anti-infection >> SARS-CoV
In Vitro	In a cytopathic effect (cpe)-inhibition assay of SARS-CoV-2 infected VeroE6/TMPRSS2 cells, Ensitrelvir shows the EC50 values are approximately 0.4 μM for both wild-type virus and Alpha, Beta, Gamma and Delta variants. EC50 values for SARS-CoV and MERS-CoV were 0.21 and 1.4 μM respectively[1].
In Vivo	Ensitrelvir dose-dependently inhibits intrapulmonary replication of SARS-CoV-2 in mice[2].
References	[1]. McKimm-Breschkin JL, et al. COVID-19, Influenza and RSV: Surveillance-informed prevention and treatment - Meeting report from an isirv-WHO virtual conference. Antiviral Res. 2022;197:105227. [2]. Yuto Unoh, et al. Discovery of S-217622, a Non-Covalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19. bioRxiv 2022.01.26.477782.

Molecular Formula	C₂₂H₁₇ClF₃N₉O₂
Molecular Weight	531.88